Additivity of Pilocarpine to Bimatoprost in Ocular Hypertension and Early Glaucoma

Toor, A.; Chanis, R.A.; Polikoff, Lee; Fahim, Magid M; Sinha, Anshu P; Serle, Janet B.

doi:10.1097/01.ijg.0000151888.59165.74

Search citation statements

Order By: Relevance

Paper Sections

Select...

Selecting An Ocular Hypotensive Agent1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2015

Publication Types

Select...

Article3

Book3

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 9 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When added to bimatoprost at concentrations of 2%, 4%, and 6%, pilocarpine was reported to be neither additive nor antagonistic to the ocular hypotensive efficacy of bimatoprost (Toor et al 2005). …”

Section: Selecting An Ocular Hypotensive Agentmentioning

confidence: 99%

The management of glaucoma and intraocular hypertension: current approaches and recent advances

Noecker¹

2006

Therapeutics and Clinical Risk Management

View full text Add to dashboard Cite

Abstract:In the last decade, numerous novel ocular hypotensive agents have been introduced for the control of intraocular pressure (IOP). Clinicians now have more options than ever in the selection of medical therapy for the treatment of glaucoma and ocular hypertension. When selecting an ocular hypotensive medication for their patients, clinicians should consider not only the IOP-lowering efficacy of an agent, but also the ability of the drug to allow patients to achieve target levels of IOP that are low enough to stop the progression of glaucomatous damage. Other considerations should include how well the drug controls diurnal IOP, the likelihood of serious adverse events, the versatility of the medication for use as an adjunctive agent, as well as other potential attributes (ie, neuroprotection).

show abstract

Section: Selecting An Ocular Hypotensive Agentmentioning

confidence: 99%